Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astra Joint Venture Keeps Paying Dividends For Merck; “True Up” Due In 2008

Executive Summary

AstraZeneca is still estimating that its final payment in the break-up of the Merck joint venture will be $4.7 bil. in 2008
Advertisement

Related Content

AstraZeneca’s Gut Instinct: CEO-Designate Is Nexium Brand Builder Brennan
AstraZeneca’s Gut Instinct: CEO-Designate Is Nexium Brand Builder Brennan
Nexium Discounts Still Capturing “Value” For Brand, AstraZeneca Says
Merck Succession Plan: Board Wants “Internal” Successor, CEO Says
Quarterly Earnings Calls, In Brief
AstraZeneca Exanta Liver Safety Is Key Approval Issue, Company Says
Advertisement
UsernamePublicRestriction

Register

PS043957

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel